Table 1 Epidemiological and clinicopathological characteristics of patients within three groups.

From: The clinicopathological characteristics and survival outcomes of endometrial carcinoma coexisting with or arising in adenomyosis: A pilot study

Parameter

Group A EEC without AM (n = 1043)

Group B EEC-A

Group C EEC-AIA

P value

All (n = 230)

Stage IA (n = 199)

All (n = 28)

Stage IA (n = 24)

Between three groups

Between stage IA patients of three groups

Age (year), mean ± SD

53.35 ± 9.97

54.50 ± 9.06

53.96 ± 8.99

48.39 ± 8.61

48.62 ± 9.19

0.006

0.043

Height (cm), mean ± SD

160.80 ± 5.89

161.11 ± 4.53

161.08 ± 4.58

159.86 ± 4.37

160.25 ± 4.55

0.488

0.714

Weight (kg), mean ± SD

67.44 ± 11.60

67.34 ± 10.93

67.36 ± 11.11

67.43 ± 14.16

67.21 ± 14.86

0.993

0.993

BMI (kg/m2), mean ± SD

26.13 ± 4.54

25.91 ± 4.01

25.92 ± 4.00

26.39 ± 5.66

26.17 ± 5.81

0.751

0.828

Menopause, n (%)

666 (63.85)

154 (66.96)

129 (64.80)

13 (46.43)

12 (50.00)

0.098

0.356

Metabolic disease, n (%)

395 (37.87)

86 (37.39)

71 (35.68)

14 (50.00)

12 (50.00)

0.416

0.386

Infertility, n (%)

20 (1.92)

4 (1.74)

4 (2.01)

2 (7.14)

1 (4.17)

0.142

0.735

Situation of fertility, n (%)

    Gravidity

2.42 ± 1.37

2.33 ± 1.26

2.34 ± 1.27

1.43 ± 1.17

1.50 ± 1.22

0.001

0.004

    Parity

1.29 ± 0.90

1.30 ± 0.91

1.28 ± 0.93

0.71 ± 0.66

0.79 ± 0.66

0.003

0.027

Endometriosis*, n (%)

21 (2.01)

18 (7.83)

13 (6.53)

2 (7.14)

1 (4.17)

<0.001

0.002

Ovarian EM

10 (0.96)

13 (5.65)

8 (4.02)

2 (7.14)

1 (4.17)

<0.001

0.003

Peritoneum EM

11 (1.05)

12 (5.22)

10 (5.02)

2 (7.14)

1 (4.17)

<0.001

<0.001

DIE

9 (0.86)

10 (4.35)

9 (4.52)

0 (0)

0 (0)

<0.001

<0.001

Surgical routes, n (%)

     

0.003

<0.001

    Laparoscopy

779 (74.69)

196 (85.22)

174 (87.44)

21 (75.00)

19 (79.17)

  

    Laparotomy

264 (25.31)

34 (14.78)

25 (12.56)

7 (25.00)

5 (2.51)

  

Surgical procedures, n (%)

     

0.735

0.467

    Simple hysterectomy

373 (35.76)

82 (35.65)

80 (40.20)

8 (28.57)

8 (33.33)

  

    Staging surgeries

670 (64.24)

148 (64.35)

119 (59.80)

20 (71.43)

16 (66.67)

  

Ovarian preservation, n (%)

31 (2.97)

7 (3.04)

7 (35.18)

1 (3.57)

1 (4.17)

0.982

0.877

Differential of endometrioid EC, n (%)

     

0.028

0.003

    Grade 1

706 (67.69)

176 (76.52)

159 (79.90)

24 (85.71)

21 (87.50)

  

    Grade 2

278 (26.65)

44 (19.13)

35 (17.59)

4 (14.29)

3 (12.50)

  

    Grade 3

59 (5.66)

10 (4.35)

5 (2.51)

0 (0)

0 (0.00)

  

FIGO stages

     

<0.001

—

    Stage I-II, n (%)

1043 (100)

220 (95.65)

199 (100.00)

25 (89.29)

24 (100.00)

  

    Stage III-IV, n (%)

0 (0)

10 (4.35%)

0 (0)

3 (10.71)

0 (0)

  

Maximum diameter of the tumor (mm), mean ± SD

23.26 ± 18.02

20.53 ± 18.06

19.72 ± 18.79

18.29 ± 9.03

17.58 ± 8.96

0.047

0.016

Positive LVSI, n (%)

55 (5.27)

22 (9.57)

14 (7.04)

2 (7.14)

1 (4.17)

0.046

0.583

dMMR deficiency, n/n (%)

251/882 (28.46)

40/186 (21.5)

35/154(22.73)

4/28 (14.33)

3/20 (15.00)

0.047

<0.001

ER, n (%)

998 (95.68)

222 (96.52%)

189 (94.97)

27 (96.43)

24 (100.00)

0.837

0.518

PR, n (%)

1001 (95.97)

224 (97.39)

188 (94.47)

27 (96.43)

23 (95.83)

0.557

0.631

Postoperative adjuvant therapy, n (%)

84 (8.05)

34 (14.78)

14 (7.04)

4 (14.29)

1 (4.17)

0.004

0.707

Postoperative radiotherapy, n (%)

59 (5.66)

18 (7.83)

6 (3.02)

2 (7.14)

1 (4.17)

0.447

0.299

Postoperative chemotherapy, n (%)

36 (3.45)

16 (6.96)

5 (2.51)

3 (10.71)

0 (0)

0.013

0.525

Recurrence, n (%)

35 (3.36)

14 (6.17)

4 (2.00)

0 (0)

0 (0)

0.077

0.423

Recurrent sites, n (%)

33

13

4

0 (0)

0 (0)

0.184

0.954

    Within the pelvic cavity

16 (1.53)

3 (1.32)

2 (50.00)

0 (0)

0 (0)

  

    Distant sites

17 (1.63)

10 (4.41)

2 (50.00)

0 (0)

0 (0)

  

Mortality, n (%)

16 (1.53)

9 (3.96)

4 (2.00)

0 (0)

0 (0)

0.041

0.727

Mortality due to cancer, n (%)

11 (1.05)

6 (2.64)

3 (1.50)

0 (0)

0 (0)

0.135

0.743

  1. Abbreviations: AM, adenomyosis; DIE, deep invasive endometriosis; dMMR, DNA mismatch repair; EEC, endometrial endometrioid carcinoma; EEC-A, endometrial endometrioid carcinoma coexisting with adenomyosis; EEC-AIA, endometrial endometrioid carcinoma arising in adenomyosis; ER, estrogen receptor; EM, endometriosis; LVSI, lymph-vascular space invasion; NA, not available; PALN, para-aortic lymph nodes; PR, progestrone receptor; SD, standard deviation.
  2. *Some patients might have more than one subtype of endometriosis.
Back to article page